DIOPSYS: Evaluation of the Electroretinogram Pattern (Diopsys® NOVA System) for the Early Diagnosis of Glaucoma

Sponsor
Groupe Hospitalier Paris Saint Joseph (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03642782
Collaborator
(none)
12
1
1
53.9
0.2

Study Details

Study Description

Brief Summary

Glaucoma is a common and potentially blinding disease. It is characterized by an optic nerve damage, a visual field defect and elevated intraocular pressure (IOP).

The loss of retinal nerve fibers is accompanied by functional impairment in the territories corresponding to deficits of the visual field. However, this structure-function relationship is not always found initially. These discrepancies are mainly chronological: the structural damage preceding the functional impairment sometimes of several years

Condition or Disease Intervention/Treatment Phase
  • Device: Electroretinogram Pattern (Diopsys® NOVA System)
N/A

Detailed Description

The electroretinogram pattern (ERGP) is an electrophysiological exploration technique that reflects the activity of retinal ganglion cells. It presents itself as an objective field of vision that does not require the active collaboration of the patient. It consists in recording the electrical activity of functional retinal ganglion cells following a light stimulation. Simple (30 minutes maximum), it could improve the detection of early forms of glaucoma. A significant ERGP is also thought to be correlated with peripapillary and macular CNP structural involvement of the ganglionic complex in early forms of glaucoma (MD> -6 dB).

Some results even suggest that ganglion dysfunction could be detected by the ERGP eight years on average before the occurrence of detectable alterations on the RNFL OCT. ERGP is already recognized as a routine examination for monitoring glaucomatous patients (review side in nomenclature and reimbursed by Social Security) but it could therefore be used as a diagnostic tool in very early forms of intraocular hypertonia glaucoma so to objectify signs of preperimetric functional impairment in order to establish a suitable hypotonizing treatment and to improve the prognosis of this disease.

Study Design

Study Type:
Interventional
Actual Enrollment :
12 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Evaluation of the Electroretinogram Pattern (Diopsys® NOVA System) for the Early Diagnosis of Glaucoma
Actual Study Start Date :
Jul 3, 2018
Actual Primary Completion Date :
Jul 2, 2019
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: early age of glaucoma or with important risk factors

All patients included will benefit from a complete ophtalmic examination including visual acuity, slit lamp biomicroscopic examination of the anterior segment, measurement of intraocular pressure by Goldmann tonometer aplanation, dynamic gonioscopy with Posner glass. They will also have a fundus examination with examination of the retina, macula and optic nerve as well as the ERGP.

Device: Electroretinogram Pattern (Diopsys® NOVA System)
it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes

Outcome Measures

Primary Outcome Measures

  1. Correlations between Electroretinogram Pattern, vision field and optical coherence tomography [Time of inclusion]

    Electroretinogram Patterny : Magnitude, magnitude D, Magnitude D/Magnitude ratio.

  2. Correlations between Electroretinogram Pattern, vision field and optical coherence [Time of inclusion]

    Vision field: mean deviation, corrected pattern standard deviation.

  3. Correlations between Electroretinogram Pattern, vision field and optical coherence [Time of inclusion]

    Optical coherence tomography: retinal nerve fiber layer thickness and macular analysis of the ganglionic complex.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Man and woman age ≥ 18 years

  • Francophone

  • Patient with medical insurance

  • Refraction: sphere ± 5.0 D and cylinder ± 3.0 D

  • Pupillary diameter ≥ 3mm

  • Early glaucoma patients :

  • Intraocular pressure> 21 mmHg or <21mmHg under treatment

  • Thickness of pathological retinal nerve fibers with at least one affected area (OCT)

  • At least one reliable visual field (false positives, false negatives and fixation losses ≤ 25%) and no artifacts, with Corrected Pattern Standard Deviation (CPSD) pathological in the 5% and Glaucoma Hemifield Pathological test and an early attack (MD> -6dB)

  • Patient at risk for glaucoma with:

  • And / or family history of glaucoma

  • and / or intraocular pressure> 21 mmHg

  • and / or retinal nerve fibers (pathological thickness in at least one area on the OCT)

  • and / or reliable visual field (false positives, false negatives and fixation losses ≤ 25%) and without artifact, with pathological Corrected Pattern Standard Deviation (CPSD) in the 5% and Glaucoma Hemifield Pathological Test and an early onset (MD> -6 dB).

Exclusion Criteria:
  • Visual acuity below 20/30 (Snellen scale or equivalent on another visual acuity scale)

  • Unreliable visual field (false positives, loss of fixation and false negatives> 25%)

  • History of intraocular surgery (except uncomplicated cataract surgery)

  • Ocular pathology other than associated glaucoma

  • Neurological disease affecting the visual field or the optic nerve

  • History of macular laser or pan retinal photocoagulation

  • Unreliable ERGP pattern

  • Offset OCT, unreliable

  • Refusal to participate in the study

  • Patient under tutorship or curatorship

  • Patient deprived of liberty

  • Epileptic patient

  • Eczema of the eyelids or allergy to one of the components of the electrodes or skin gel allowing the cleaning of the skin before the positioning of the electrodes.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Groupe Hospitalier Paris Saint-Joseph Paris France 75014

Sponsors and Collaborators

  • Groupe Hospitalier Paris Saint Joseph

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Groupe Hospitalier Paris Saint Joseph
ClinicalTrials.gov Identifier:
NCT03642782
Other Study ID Numbers:
  • DIOPSYS
First Posted:
Aug 22, 2018
Last Update Posted:
Jun 30, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Groupe Hospitalier Paris Saint Joseph
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 30, 2022